Cannara Biotech Inc. (LOVFF)
| Previous Close | 0.5913 |
| Open | 0.5913 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.5913 - 0.5913 |
| 52 Week Range | 0.4926 - 0.8398 |
| Volume | |
| Avg. Volume | 1,758 |
| Market Cap | 53.228M |
| Beta (5Y Monthly) | 1.14 |
| PE Ratio (TTM) | 8.45 |
| EPS (TTM) | 0.0700 |
| Earnings Date | Jul 25, 2024 - Jul 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.Cannara Biotech Second Quarter 2024 Earnings: CA$0.038 loss per share (vs CA$0.007 loss in 2Q 2023)
Cannara Biotech ( CVE:LOVE ) Second Quarter 2024 Results Key Financial Results Revenue: CA$19.7m (up 51% from 2Q 2023...
PR NewswireCannara Biotech Reports Q2 2024 Financial Results
Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Quebec spanning over 1,650,000 sq. ft., today announced its fiscal second quarter 2024 financial and operating results for the three and six-month periods ended February 29, 2024. The full set of condensed interim consolidated financial statements for the three
- Market Exclusive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Key Takeaways; Psychedelic Sector Below is a weekly roundup on the cannabis and psychedelic sectors. In this ever-evolving landscape, we explore the major developments and groundbreaking initiatives happening among companies operating in these industries; from advancements in medical research, therapeutic applications to shifts in legal frameworks and current market trends. Top […]
